WO1997025429A1
(en)
|
1996-01-04 |
1997-07-17 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
EP2277894A1
(en)
|
2000-10-27 |
2011-01-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic acids and proteins from streptococcus groups A & B
|
EP1415005B1
(en)
|
2000-12-07 |
2012-11-21 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
CA2438942A1
(en)
*
|
2001-02-23 |
2002-09-26 |
Glaxosmithkline Biologicals S.A. |
Influenza vaccine formulations for intradermal delivery
|
DE10125731A1
(de)
*
|
2001-05-17 |
2003-03-06 |
A I D Autoimmun Diagnostika Gm |
Darreichungsform von immunologischen Wirkstoffen
|
MY134424A
(en)
*
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
US7501134B2
(en)
|
2002-02-20 |
2009-03-10 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
AU2003276679A1
(en)
|
2002-06-13 |
2003-12-31 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
DK1549338T3
(da)
|
2002-10-11 |
2011-03-28 |
Novartis Vaccines & Diagnostic |
Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
EP2289546A3
(en)
|
2003-01-30 |
2011-03-30 |
Novartis Vaccines and Diagnostics S.r.l. |
Injectable vaccines against multiple meningococcal serogroups
|
ES2423800T3
(es)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
ES2529736T3
(es)
|
2003-04-10 |
2015-02-25 |
Novartis Vaccines And Diagnostics, Inc. |
Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
|
CN100438964C
(zh)
*
|
2003-05-15 |
2008-12-03 |
广州市白云化工实业有限公司 |
一种非离子型活性硅表面活性剂及其制备方法
|
DE602004022286D1
(de)
|
2003-06-02 |
2009-09-10 |
Novartis Vaccines & Diagnostic |
Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1961426B1
(en)
|
2003-10-02 |
2011-04-27 |
Novartis Vaccines and Diagnostics S.r.l. |
Combined meningitis vaccines
|
EP1722815A1
(en)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza virus vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
SI1740217T1
(sl)
|
2004-04-30 |
2011-10-28 |
Novartis Ag |
Konjugirano meningokokno cepljenje
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2848692B1
(en)
|
2004-05-21 |
2017-08-16 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
EP1784211A4
(en)
|
2004-07-29 |
2010-06-30 |
Novartis Vaccines & Diagnostic |
IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
PT2682126T
(pt)
|
2005-01-27 |
2017-02-28 |
Children`S Hospital & Res Center At Oakland |
Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
NZ597685A
(en)
|
2005-02-18 |
2013-12-20 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
NZ560929A
(en)
|
2005-02-18 |
2009-12-24 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
EP1945247A1
(en)
|
2005-10-18 |
2008-07-23 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
HUE051122T2
(hu)
|
2005-11-04 |
2021-03-01 |
Seqirus Uk Ltd |
Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
|
JP5215865B2
(ja)
|
2005-11-22 |
2013-06-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
ノロウイルス抗原およびサポウイルス抗原
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
EP1976559B3
(en)
|
2006-01-27 |
2020-02-19 |
Seqirus UK Limited |
Influenza vaccines containing hemagglutinin and matrix proteins
|
US8535683B2
(en)
|
2006-03-22 |
2013-09-17 |
Abbott Biologicals B.V. |
Intranasal or inhalational administration of virosomes
|
EP2010537B1
(en)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
WO2007110776A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
EP2382988A1
(en)
|
2006-03-31 |
2011-11-02 |
Novartis AG |
Combined mucosal and parenteral immunization against HIV
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
WO2008032219A2
(en)
|
2006-09-11 |
2008-03-20 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
GB0622282D0
(en)
|
2006-11-08 |
2006-12-20 |
Novartis Ag |
Quality control methods
|
EP2532362A1
(en)
|
2006-12-06 |
2012-12-12 |
Novartis AG |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
AU2008335457B2
(en)
|
2007-12-07 |
2015-04-16 |
Glaxosmithkline Biologicals S.A. |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
RU2498994C2
(ru)
|
2007-12-21 |
2013-11-20 |
Новартис Аг |
Мутантные формы стрептолизина о
|
CN102356089B
(zh)
|
2008-02-21 |
2014-02-19 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽
|
US9511131B2
(en)
|
2008-03-10 |
2016-12-06 |
Children's Hospital & Research Center Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
NZ592977A
(en)
|
2008-12-09 |
2013-01-25 |
Pfizer Vaccines Llc |
IgE CH3 PEPTIDE VACCINE
|
CN102481349B
(zh)
|
2009-01-12 |
2014-10-15 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
EP2396032B1
(en)
|
2009-02-10 |
2016-09-28 |
Seqirus UK Limited |
Influenza vaccines with reduced amounts of squalene
|
CA2754618A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
JP5551774B2
(ja)
|
2009-06-15 |
2014-07-16 |
ナショナル ユニヴァーシティー オブ シンガポール |
インフルエンザワクチン、組成物、および使用方法
|
US10988511B2
(en)
|
2009-07-07 |
2021-04-27 |
Glaxosmithkline Biologicals Sa |
Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
|
HUE058971T2
(hu)
|
2009-07-15 |
2022-09-28 |
Glaxosmithkline Biologicals Sa |
RSV F fehérjekészítmények és eljárások azok elõállítására
|
SI2464658T1
(sl)
|
2009-07-16 |
2015-02-27 |
Novartis Ag |
Detoksificirani imunogeni escherichie coli
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
EP2470204B1
(en)
|
2009-08-27 |
2015-12-16 |
GlaxoSmithKline Biologicals SA |
Hybrid polypeptides including meningococcal fhbp sequences
|
MY163512A
(en)
|
2009-09-03 |
2017-09-15 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
CN102596254B
(zh)
|
2009-09-30 |
2016-10-19 |
诺华股份有限公司 |
金黄色葡萄球菌5型和8型荚膜多糖的偶联
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
AU2010310985B2
(en)
|
2009-10-27 |
2014-11-06 |
Glaxosmithkline Biologicals S.A. |
Modified meningococcal fHBP polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP2515934B1
(en)
|
2009-12-22 |
2017-05-17 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
TR201802933T4
(tr)
|
2010-03-30 |
2018-03-21 |
Childrens Hospital & Res Center At Oakland |
Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011127316A1
(en)
|
2010-04-07 |
2011-10-13 |
Novartis Ag |
Method for generating a parvovirus b19 virus-like particle
|
EP2558069A1
(en)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridine compositions and uses thereof
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
WO2011154863A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
CA2804501C
(en)
|
2010-07-06 |
2021-01-26 |
Novartis Ag |
Noro virus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
RU2013155485A
(ru)
|
2011-05-13 |
2015-06-20 |
Новартис Аг |
Антигены f rsv в конформации "перед слиянием"
|
WO2013006842A2
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
TR201808684T4
(tr)
|
2012-10-02 |
2018-07-23 |
Glaxosmithkline Biologicals Sa |
Lineer olmayan sakarit konjügatları.
|
JP6266000B2
(ja)
|
2012-10-03 |
2018-01-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
CN111249455A
(zh)
|
2012-11-30 |
2020-06-09 |
葛兰素史密丝克莱恩生物有限公司 |
假单胞菌抗原和抗原组合
|
WO2015132619A1
(en)
|
2013-05-15 |
2015-09-11 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9675064B2
(en)
*
|
2013-10-03 |
2017-06-13 |
Dow Global Technologies Llc |
Microbicidal composition
|
WO2015079952A1
(ja)
*
|
2013-11-29 |
2015-06-04 |
テルモ株式会社 |
アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法
|
NZ759686A
(en)
|
2014-01-21 |
2023-07-28 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US10279019B2
(en)
|
2014-02-11 |
2019-05-07 |
Stc.Unm |
PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
|
RU2714248C2
(ru)
|
2014-07-23 |
2020-02-13 |
Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд |
Варианты фактор н-связывающего белка и способы их применения
|
ES2945312T3
(es)
|
2015-01-15 |
2023-06-30 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
EP3302536A1
(en)
|
2015-06-03 |
2018-04-11 |
Affiris AG |
Il-23-p19 vaccines
|
CN107849119A
(zh)
|
2015-07-07 |
2018-03-27 |
阿费里斯股份公司 |
用于治疗和预防IgE介导的疾病的疫苗
|
SG10202005253TA
(en)
|
2015-07-21 |
2020-07-29 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP3377098A1
(en)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogenic compositions for use in pneumococcal vaccines
|
TW202111125A
(zh)
|
2016-01-19 |
2021-03-16 |
美商輝瑞股份有限公司 |
癌症疫苗
|
WO2018134693A1
(en)
|
2017-01-20 |
2018-07-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
EP3952906A1
(en)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CA3159573A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
AU2021224078B2
(en)
|
2020-02-21 |
2024-01-18 |
Pfizer Inc. |
Purification of saccharides
|
BR112022014555A2
(pt)
|
2020-02-23 |
2022-09-20 |
Pfizer |
Composições de escherichia coli e métodos das mesmas.
|
JP2023546615A
(ja)
|
2020-10-27 |
2023-11-06 |
ファイザー・インク |
大腸菌組成物およびその方法
|
CN116744965A
(zh)
|
2020-11-04 |
2023-09-12 |
辉瑞大药厂 |
用于肺炎球菌疫苗的免疫原性组合物
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
TW202245836A
(zh)
|
2021-02-19 |
2022-12-01 |
美商賽諾菲巴斯德公司 |
重組b型腦膜炎球菌疫苗
|
WO2022234483A1
(en)
|
2021-05-04 |
2022-11-10 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
TW202304503A
(zh)
|
2021-05-28 |
2023-02-01 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
WO2023062170A2
(en)
*
|
2021-10-15 |
2023-04-20 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
KR102631297B1
(ko)
*
|
2021-11-09 |
2024-01-30 |
주식회사에이치엔비랩스 |
표면처리를 통해 안정성이 향상된 나노좀의 제조방법
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
WO2024082281A1
(en)
*
|
2022-10-21 |
2024-04-25 |
Nanjing Haiwei Pharmaceutical Technologies Co., Ltd. |
Novel formulations of epinephrine and uses thereof
|